We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
+33.73%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$2.59B
AUM Growth
+$475M
Cap. Flow
-$61.5M
Cap. Flow %
-2.37%
Top 10 Hldgs %
31.64%
Holding
140
New
7
Increased
46
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
CVET
Covetrus, Inc. Common Stock
CVET
+$23.1M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$16.6M
3
CI icon
Cigna
CI
+$16.4M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$15M
5
TVTX icon
Travere Therapeutics
TVTX
+$9.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$44.7M
2
LOXO
Loxo Oncology, Inc
LOXO
+$33.8M
3
MOH icon
Molina Healthcare
MOH
+$18.2M
4
WCG
Wellcare Health Plans, Inc.
WCG
+$18M
5
BIIB icon
Biogen
BIIB
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.8%
2 Miscellaneous 1.82%
3 Consumer Staples 0.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
101
Rhythm Pharmaceuticals
RYTM
$6.83B
$5.93M 0.23%
216,500
– –
MNTA
102
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$5.81M 0.22%
400,000
– –
ELV icon
103
Elevance Health
ELV
$90.2B
$5.74M 0.22%
+20,000
New +$5.78M
BCRX icon
104
BioCryst Pharmaceuticals
BCRX
$2.1B
$5.7M 0.22%
700,000
– –
ARDX icon
105
Ardelyx
ARDX
$878M
$5.6M 0.22%
2,000,000
– –
MGNX icon
106
MacroGenics
MGNX
$255M
$5.39M 0.21%
300,000
+219,019
+270% +$3.79M
CGEN icon
107
Compugen
CGEN
$231M
$4.55M 0.18%
1,100,000
– –
NBRV
108
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.9M 0.15%
6,400
– –
CORV
109
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$3.79M 0.15%
1,200,000
– –
ADAP
110
DELISTED
Adaptimmune Therapeutics
ADAP
$3.44M 0.13%
800,000
+50,000
+7% +$233K
CHMA
111
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.38M 0.13%
650,000
+125,000
+24% +$551K
DVAX
112
DELISTED
Dynavax Technologies
DVAX
$2.78M 0.11%
380,000
– –
ACET icon
113
Adicet Bio
ACET
$84.3M
$2.73M 0.11%
3,571
– –
PRTK
114
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.41M 0.09%
450,000
– –
ARVN icon
115
Arvinas
ARVN
$534M
$2.21M 0.09%
150,000
– –
NVRO
116
DELISTED
NEVRO CORP.
NVRO
$2.17M 0.08%
+34,700
New +$1.63M
NVAX icon
117
Novavax
NVAX
$1.53B
$1.79M 0.07%
162,500
– –
LJPC
118
DELISTED
La Jolla Pharmaceutical Company
LJPC
$1.78M 0.07%
277,236
– –
CRVS icon
119
Corvus Pharmaceuticals
CRVS
$1.06B
$1.61M 0.06%
400,000
– –
KLDO
120
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$1.45M 0.06%
+100,050
New +$1.38M
SLDB icon
121
Solid Biosciences
SLDB
$905M
$552K 0.02%
4,000
+67
+2% +$16.8K
KA
122
DELISTED
Kineta, Inc. Common Stock
KA
$504K 0.02%
2,857
– –
BIIB icon
123
Biogen
BIIB
$32.2B
– –
-50,000
Closed -$15.7M
DVA icon
124
DaVita
DVA
$12.2B
– –
-215,200
Closed -$11.1M
EXEL icon
125
Exelixis
EXEL
$14.2B
– –
-621,400
Closed -$12.2M
2 3 4
5
6

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Rock Springs Capital Management held 140 positions worth $2.59B, up 22% from $2.12B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rock Springs Capital Management's Q1 2019 filing shows 7 new, 46 increased, 13 reduced and 9 closed positions. Its largest new stake was Covetrus, Inc. Common Stock: 650,000 shares worth $20.7M. The largest sale was TESARO, Inc., an estimated $44.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Rock Springs Capital Management's largest Q1 2019 buy was Covetrus, Inc. Common Stock: 650,000 shares worth $20.7M.
  • Rock Springs Capital Management added most to Portola Pharmaceuticals, Inc. in Q1 2019, an estimated $16.6M increase.
  • Rock Springs Capital Management's biggest Q1 2019 reduction was Molina Healthcare, cutting an estimated $18.2M.
  • Rock Springs Capital Management fully exited TESARO, Inc. in Q1 2019, selling an estimated $44.7M.
  • Rock Springs Capital Management's ten largest holdings make up 32% of its $2.59B portfolio in Q1 2019.
  • Rock Springs Capital Management opened 7 new positions and closed 9 in Q1 2019.
  • Rock Springs Capital Management's portfolio value rose 22% quarter-over-quarter to $2.59B.

Based on Rock Springs Capital Management's 13F filing for Q1 2019, filed 15 May 2019.